切换至 "中华医学电子期刊资源库"
高级检索
中华肾病研究电子杂志

中华肾病研究电子杂志 ›› 2020, Vol. 09 ›› Issue (01) : 17 -21. doi: 10.3877/cma.j.issn.2095-3216.2020.01.004

所属专题： 指南与规范； 文献； 指南共识；

专家论坛

《中国慢性肾脏病矿物质和骨异常诊治指南》的解读与思考
余永武1, 周加军2, 张凌3,†()   
  1. 1. 100022　北京，清华大学附属垂杨柳医院
    2. 241000　芜湖，皖南医学院弋矶山医院
    3. 100029　北京，中日友好医院肾内科
  • 收稿日期:2019-11-18 出版日期:2020-02-28
  • 通信作者: 张凌
  • 基金资助:
    吴阶平医学基金支持项目(320.6750.18110)

Interpretation and thinking of the "China guidelines for diagnosis and treatment of chronic kidney disease-mineral and bone disorder"

Yongwu Yu1, JiaJun Zhou2, Ling Zhang3,†()   

  1. 1. Department of Nephrology, Chuiyangliu Hospital Affiliated to Tsinghua University, Beijing 100022
    2. Blood Purification Center, Yijishan Hospital Affiliated to Wannan Medical College, Wuhu 241000, Anhui Province
    3. Department of Nephrology, China-Japan Friendship Hospital, Beijing 100029; China
  • Received:2019-11-18 Published:2020-02-28
  • Corresponding author: Ling Zhang
  • About author:
    Corresponding author: Zhang Ling, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

余永武, 周加军, 张凌. 《中国慢性肾脏病矿物质和骨异常诊治指南》的解读与思考[J]. 中华肾病研究电子杂志, 2020, 09(01): 17-21.

Yongwu Yu, JiaJun Zhou, Ling Zhang. Interpretation and thinking of the "China guidelines for diagnosis and treatment of chronic kidney disease-mineral and bone disorder"[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2020, 09(01): 17-21.

慢性肾脏病-矿物质和骨代谢异常(CKD-MBD)是慢性肾脏疾病最常见的并发症，是由于肾小球滤过率下降，导致多种物质、毒素潴留。临床上表现为血钙、磷及相关调节激素如甲状旁腺激素、维生素D和成纤维细胞生长因子23的紊乱，进而引起代谢性骨病或骨折、心血管疾病的发生，增加患者的住院率及病死率。2018年推出的《中国慢性肾脏病矿物质和骨异常诊治指南》为规范CKD-MBD诊疗起到了很好的作用。本文就CKD-MBD指南结合自己的临床经验体会予以解读。

关键词: 慢性肾脏病-矿物质和骨代谢异常, 继发性甲状旁腺功能亢进

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is the most common complication of chronic kidney disease. It is due to the decline in glomerular filtration rate, which leads to the retention of multiple substances and toxins. Its clinical manifestations includes disorders of blood calcium, phosphorus and related regulatory hormones such as parathyroid hormone, vitamin D, and fibroblast growth factor 23, which in turn cause metabolic bone disease or fractures, and cardiovascular diseases, and increase the hospitalization rate and mortality of patients. The "China guidelines for the diagnosis and treatment of CKD-MBD" launched in 2018 has played a very good role in standardizing the diagnosis and treatment of CKD-MBD. This article interpreted the CKD-MBD guidelines combing with the clinical experience of the authors.

Key words: Chronic kidney disease-mineral and bone disorder (CKD-MBD), Secondary hyperparathyroidism (SHPT)
[1]
Galassi A, Bellasi A, Auricchio S, et al. Which vitamin D in CKD-MBD? The time of burning questions [J]. Biomed Res Int, 2013, 2013: 864012.
[2]
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) [J]. Kidney Int Suppl (2011), 2017, 7(1): 1-59.
[3]
刘志红，李贵森．中国慢性肾脏病矿物质和骨异常诊治指南[M]. 北京：北京人民出版社，2018.
[4]
Fukagawa M, Kazama JJ, Shigematsu T. Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases [J]. Am J Kidney Dis, 2001, 38(4 Suppl 1): S152-S155.
[5]
Tentori F, Wang M, Bieber BA, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study [J]. Clin J Am Soc Nephrol, 2015, 10(1): 98-109.
[6]
周加军，张凌．活性维生素D及其类似物在CKD-MBD中的应用[J]．中国血液净化， 2018，17(6):370-373.
[7]
Fukuma S, Kurita N, Fukagawa M, et al. Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan [J]. Kidney Int Suppl (2011), 2013, 3(5): 436-441.
[8]
de Francisco AL, Belmar L, Piñera C, et al. Effect of calcium acetate/magnesium carbonate in the treatment of hyperphosphataemia in dialysis patients in real clinical practice. One year follow up [J]. Nefrologia, 2014, 34(5): 617-627.
[9]
Ketteler M, Martin KJ, Wolf M, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study [J]. Nephrol Dial Transplant, 2012, 27(8): 3270-3278.
[10]
王海峰，张凌，姚力，等．三种不同甲状旁腺切除术治疗继发性甲状旁腺功能亢进425例疗效比较[J]．中国血液净化，2016，15(9):455-458.
[11]
Sharma J, Raggi P, Kutner N, et al. Improved long-term survival of dialysis patients after near-total parathyroidectomy [J]. J Am Coll Surg, 2012, 214(4): 400-408.
[12]
Daniel WT, Weber C, Bailey JA, et al. Prospective analysis of coronary calcium in patients on dialysis undergoing a near-total parathyroidectomy [J]. Surgery, 2013, 154(6): 1315-1322.
[13]
于明安，张凌，彭丽丽，等. 超声引导微波消融术治疗继发性甲旁亢短期疗效分析[J]. 中华肾脏病杂志， 2015, 31(4):303-304.
[14]
彭成忠，陈洪宇，张正贤，等. 射频消融术治疗慢性肾脏病继发甲状旁腺功能亢进[J]. 中华肾脏病杂志， 2014, 30(11):870-871.
[1] 刘文, 罗丹, 代小雨, 鲜于剑波, 于颖娟, 钟春林, 王东. 继发性甲状旁腺功能亢进的治疗研究进展[J]. 中华肾病研究电子杂志, 2022, 11(05): 281-284.
[2] 李丹, 谢坤, 陈倩倩, 刘昌华. 继发性甲状旁腺功能亢进症术后复发的防治[J]. 中华肾病研究电子杂志, 2021, 10(03): 166-169.
[3] 王萌, 魏丽敏, 刘华, 史珂慧, 蒋红利. 甲状旁腺全切＋自体移植术治疗继发性甲状旁腺功能亢进症疗效分析[J]. 中华肾病研究电子杂志, 2019, 08(04): 170-175.
[4] 郭志勇, 李璐. 腹膜透析患者继发性甲状旁腺功能亢进的诊治[J]. 中华肾病研究电子杂志, 2016, 05(03): 108-113.
[5] 张凌. 继发性甲状旁腺功能亢进的治疗策略[J]. 中华肾病研究电子杂志, 2015, 04(03): 118-122.
[6] 周加军, 余永武, 周涵, 刘勇, 张凌. 甲状旁腺切除对继发性甲状旁腺功能亢进患者骨密度及骨代谢的影响[J]. 中华临床医师杂志(电子版), 2023, 17(06): 706-710.
[7] 周加军, 余永武, 周涵, 张凌. 358例继发性甲状旁腺功能亢进症患者异位甲状旁腺的检出及分布情况分析[J]. 中华临床医师杂志(电子版), 2023, 17(04): 381-385.
[8] 李平, 徐道亮, 刘昌华. 99TCm-甲氧基异丁基异腈在甲状旁腺切除术中定位诊断的效果评价[J]. 中华临床医师杂志(电子版), 2019, 13(06): 429-434.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号